Abstract 2062P
Background
PsyD is frequent in cancer pts and it negatively affects their treatment and quality of life. However, psychological screening is not extensively performed and few data about its impact are available. The aim of our study is to evaluate baseline PsyD in PC pts treated at our Institution and its correlation with clinicopathological features.
Methods
In the last year, we baseline evaluated PsyD of PC pts starting chemotherapy at our Institution, using the Distress Thermometer (DT) and Problem List (PL). The DT score was divided into three levels: no/minimal (0-3), moderate (4-6) and high (7-10) distress. PL was grouped into 6 categories (practical, physical, cognitive, spiritual/religious, emotional and family problems). Clinicopathological characteristics were collected and correlated with PsyD.
Results
A total of 86 PC pts were tested for baseline PsyD. The median age was 65 years, 63% were female, ECOG PS was > 1 in 56% of pts and 72% of pts had one or more comorbidities. The majority of pts (67%) received chemotherapy for metastatic disease. Regarding psychological screening, 31%, 29% and 40% of pts had no/minimal, moderate and high DT score, respectively. According to PL we observed: practical problems in 17% of patients, physical in 9%, cognitive in 42%, spiritual/religious in 9%, emotional in 16%, and family problems in 13% of patients. Regarding psycho-oncological care, 93% of pts received initial counseling, 63% intervention and follow-up. No significant association between DT score and PL groups with clinicopathological characteristics was observed.
Conclusions
Our mono-institutional analysis showed that the majority of PC pts receiving chemotherapy at our Institution presented a PsyD scored as moderate (29%) or high (40%) by DT at baseline. According to PL, the main problem concerned the cognitive sphere, specifically problems related to concentration and/or memory and self-perception. Additional analyses, including the impact of PsyD on treatment compliance, tolerability and prognosis are going.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione Policlinico Universitario Agostino Gemelli-IRCCS.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06